Skip to main content
Clinical Trials/NCT02094612
NCT02094612
Terminated
Not Applicable

Effectiveness of the Quotient® ADHD Assessment in a System of Care

Kaiser Permanente3 sites in 1 country207 target enrollmentMarch 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Attention Deficit and Disruptive Behavior Disorders
Sponsor
Kaiser Permanente
Enrollment
207
Locations
3
Primary Endpoint
Number of Participants With 25% Reduction in SNAP Scores
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

The study goal is to examine whether the use of an objective computerized neuroassessment (the Quotient System) for Attention-Deficit/Hyperactivity Disorder (ADHD) is related to improved outcomes among pediatric patients being assessed and treated for ADHD.

Detailed Description

This study is a randomized, controlled trial using a 2-phase data collection. The first phase is the initial assessment for ADHD and includes all patients eligible to be assessed for ADHD as determined by their clinician in the course of usual care. The baseline measurements will be used to compare groups at baseline, and also for longitudinal analyses of medication management. Patients are randomized at this point. Patients in both treatment arms who then receive an ADHD diagnosis and who start medication for ADHD will be eligible for the second phase of the study: three follow-up assessments over six months. Patients who do not have an ADHD diagnosis will not continue in the study, and will be treated by their clinician as usual.

Registry
clinicaltrials.gov
Start Date
March 2014
End Date
August 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients within the specified age range who are English speaking and who are presenting for ADHD assessment are eligible. An additional criterion is consent to be randomized.

Exclusion Criteria

  • Non English speaking
  • Refusal to participate

Outcomes

Primary Outcomes

Number of Participants With 25% Reduction in SNAP Scores

Time Frame: One month, 3 month and six month follow ups

Outcome measure reported is the number of participants with at least one 25% reduction in SNAP between visits. In treatment of ADHD, the therapeutic dose is defined as a 25% reduction in SNAP IV score between consecutive clinic visits. SNAP is itemized rating scale (Swanson, Nolan, and Pelham-IV Questionnaire) designed to measure ADHD symptoms and severity on a 4 point scale. It is based on DSM IV criteria, and is designed to measure attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) symptoms in children and young adults ages 6-18.

Secondary Outcomes

  • Satisfaction With Care(Six months)
  • Other Health Services Use(Baseline to six months)
  • ADHD Symptomatology(6 months post baseline)
  • Academic Performance(Baseline and Six Months)
  • Persistence in Care(Baseline to Six Months)
  • Medication Adherence(Baseline to six months)

Study Sites (3)

Loading locations...

Similar Trials